Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Jennifer Guimbellot to Adolescent

This is a "connection" page, showing publications Jennifer Guimbellot has written about Adolescent.

 
Connection Strength
  
 
 
0.495
  
  1. Bailey J, Rose NR, Chalamalla AR, Anderson JD, Baker E, Guimbellot JS. Assessing Dietary Patterns and Composition Among Adults With Cystic Fibrosis Taking Highly Effective Modulator Therapy. Pediatr Pulmonol. 2026 Mar; 61(3):e71532.
    View in: PubMed
    Score: 0.106
  2. Rose NR, Chalamalla AR, Garcia BA, Krick S, Bergeron J, Sadeghi H, Schellhase DE, Ryan KJ, Dowell AE, Acosta EP, Guimbellot JS. Pharmacokinetic variability of CFTR modulators from standard and alternative regimens. Pulm Pharmacol Ther. 2024 Sep; 86:102301.
    View in: PubMed
    Score: 0.094
  3. Smith M, Ryan KJ, Gutierrez H, Sanchez LHG, Anderson JN, Acosta EP, Benner KW, Guimbellot JS. Ivacaftor-elexacaftor-tezacaftor and tacrolimus combination in cystic fibrosis. J Cyst Fibros. 2022 01; 21(1):e8-e10.
    View in: PubMed
    Score: 0.076
  4. Guimbellot J, Solomon GM, Baines A, Heltshe SL, VanDalfsen J, Joseloff E, Sagel SD, Rowe SM. Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutations. J Cyst Fibros. 2019 01; 18(1):102-109.
    View in: PubMed
    Score: 0.061
  5. Reigart JR, Cash J, Siu A, Haunani Foster J, Guimbellot JS, Horton DB, Varadi EA, Lehmann CU. Generic and Biosimilar Prescribing in Children and Adolescents: Policy Statement. Pediatrics. 2026 Jun 01; 157(6).
    View in: PubMed
    Score: 0.027
  6. Reigart JR, Cash J, Siu A, Haunani Foster J, Guimbellot JS, Horton DB, Lehmann CU, Varadi EA. Generic and Biosimilar Prescribing in Children and Adolescents: Technical Report. Pediatrics. 2026 Jun 01; 157(6).
    View in: PubMed
    Score: 0.027
  7. Harris WT, Baker EH, Guimbellot JS, Collaco JM, Schechter MS, Oates GR. Tobacco smoke exposure is associated with diminished longitudinal benefit of elexacaftor/tezacaftor/ivacaftor in cystic fibrosis. J Cyst Fibros. 2025 Sep; 24(5):957-962.
    View in: PubMed
    Score: 0.025
  8. Baker E, Harris WT, Guimbellot JS, Bliton K, Rowe SM, Raju SV, Oates GR. Association between biomarkers of tobacco smoke exposure and clinical efficacy of ivacaftor in the G551D observational trial (GOAL). J Cyst Fibros. 2024 Sep; 23(5):959-966.
    View in: PubMed
    Score: 0.024
  9. Oates GR, Mims C, Geurs R, Bergquist R, Hager A, Guimbellot JS, Hartzes AM, Gutierrez HH. Mobile health platform for self-management of pediatric cystic fibrosis: Impact on patient-centered care outcomes. J Cyst Fibros. 2023 09; 22(5):823-829.
    View in: PubMed
    Score: 0.022
  10. Secunda KE, Guimbellot JS, Jovanovic B, Heltshe SL, Sagel SD, Rowe SM, Jain M. Females with Cystic Fibrosis Demonstrate a Differential Response Profile to Ivacaftor Compared with Males. Am J Respir Crit Care Med. 2020 04 15; 201(8):996-998.
    View in: PubMed
    Score: 0.018
  11. Sanders CD, Guimbellot JS, Muhlebach MS, Lin FC, Gilligan P, Esther CR. Tracheostomy in children: Epidemiology and clinical outcomes. Pediatr Pulmonol. 2018 09; 53(9):1269-1275.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.